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For the last four decades the diagnosis of MIhas been based on the WHO criteria. The
definition of MI required the presence of at 
least two of the following three factors: clinical
history of ischemic chest pain; serial changes
in ECG; a rise and fall in serum cardiac enzy-
mes. These criteria have been extensively mo-
dified by the clinicians in their application:
chest pain is often non-specific; the ECG crite-
ria were based on evolving Q-waves. Today we
know that about one-half of all infarcts are
non-Q wave. However, ST-T changes without Q
waves do not differentiate between myocardial
ischemia and MI. We have come to rely hea-
vily on biochemical markers which have been,
for the last two decades, total CK and CKMB.
Refinement of this definition has expanded
it to include the use of more sensitive and spe-
cific cardiac markers, including troponins.
They are structural proteins of the sarcomere
and would be released only with ischemia. So,
biomarkers of myocardial necrosis have, in re-
cent years, become the cornerstone of myocar-
dial necrosis in the clinical context of ische-
mia.
A new definition of MI was needed.
The basic concept behind this definition is
that any amount of myocardial necrosis caused
by ischemia should be labelled as an infarct.
Consequently any patient who was formerly
considered as having angina pectoris, stable or
unstable, could be diagnosed today as having a
small MI.
The modern concept of the pathophysiology
of acute coronary syndromes (ACS) has been
previously explained in this session by Prof.
Paulo Ribeiro. The clinical picture of ACS
may present with two different ECG patterns,
ST elevation and non-ST elevation, that may
progress to MI (Fig. 1). In the first situation
the changes include new ST segment elevation
at the J point in two or more contiguous leads
with the cut-off points of 0.2mV in leads V1-
V3 and 0.1 mV in the other leads. In patients
without ST segment elevation, we may find ST
segment depression or T wave abnormalities.
These ECG criteria reflect myocardial is-
chemia and are not sufficient by themselves to
define MI. The final diagnosis of MI depends
on the detection of elevated levels of cardiac
biomarkers in the blood.
The time release of various biomarkers fol-
lowing myocardial necrosis is different and so
we may choose the most appropriate to clarify
the clinical picture according to its character-
istics.
The most recently described biomarkers of
myocardial damage are cardiac troponin (I and
T) which are highly sensitive and specific,
thereby reflecting even microscopic zones of
myocardial necrosis. The value for troponin
must present elevated on at least one occasion
during the first 24 hours after the index clin-
ical event.
In the absence of technology for detection
of troponin, CK-MB is the best alternative. It
is less tissue specific than troponins but has
the advantage of earlier peak value and more
robust data documenting its clinical specificity.
The other enzyme tests in current use in
the sixties and seventies, namely total CK and
lactate dehydrogenase and its isoenzymes, are
no longer used due their low specificity.
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Alexander and co-workers for the PURSUIT
trial studied the association between minor
elevations of CK-MB level and mortality in pa-
tients with ACS without ST-segment elevation.
8250 patients were included, between Novem-
ber 1995 and January 1997. Mortality at 30
days and 6 months was assessed and multivari-
able logistic regression was used to determine
the independent prognostic significance of
peak CK-MB level. The mortality at 30 days
and 6 months increased from 1.8 % and 4.0 %,
respectively, in patients with normal peak CK-
MB levels, to 3.3 % and 6.2 % at peak CK-MB
levels 1 to 2 times normal, to 5.2 % and 7.5 %
at peak CK-MB levels 3 to 5 times normal,
and to 8.3 % and 11.0 % at peak CK-MB le-
vels greater than 10 times normal (p<0.001 for
both). The authors found a strong relationship
between a patient’s peak CK-MB level during
hospitalisation and both 30-day and 6-month
mortality. The increased risk begins with CK-
MB levels just above normal, and so even min-
or CK-MB elevations should be considered in-
dicative of MI.
The relation between troponin T and the
risk of subsequent cardiac events in unstable
coronary artery disease was evaluated in the
FRISC trial, and compared with other early
risk indicators. Nine hundred and seventy-six
patients included in a trial of low-molecular-
weight heparin in unstable CAD were followed
for 5 months after the index episode. The re-
sults showed that the risk of cardiac events
(death or MI) increased with increasing max-
imal levels of TnT obtained in the first 24
hours. There was an increase in the rate of the
combined end-point from the lower to the high-736
er quintiles of TnT. The three highest quintiles
(0.18g/l) constituted a high risk group with
4.3 %, 10.5 % and 16.1 % risk. The prognostic
value of TnT was independent of the type of
event, unstable angina or myocardial infarc-
tion.
From the same FRISC group a more recent
paper, published in JACC-2001, was designed
to study the mechanisms behind the prognostic
value of TnT in unstable CAD. Clinical char-
acteristics, findings at echocardiography and
coronary angiography and prognosis were eva-
luated in relation to different TnT levels. The
one-year risk of death in the non-invasive arm
increased by increasing levels of TnT (1.6 % to
4.6 %) whereas the risk of MI showed an invert-
ed U-shaped curve and was lower in the lowest
(5.5 %) and highest (8.4 %) TnT groups than in
the two intermediate groups (17.5 % and
16.2 %) – Fig. 2.
The conclusion is that any elevation of TnT
raises the probability of significant coronary
stenosis and is associated with an increased
risk of MI and death. The incidence of infarc-
tion is modest in the highest group of TnT val-
ues. These patients have persistent occlusion
of the culprit lesion, decreased LV function,
and high mortality.
In a very elegant editorial comment to this
paper, Elliot Antman emphasizes the import-
ance of diagnosing episodes of micro-infarction
that are below the accuracy provided by CK-
MB. In an analysis from the TIMI-3B trial the
TnI positive patients had a significantly higher
risk of mortality by 42 days even when the
analysis was restricted to the cohort of patients
with a negative CK-MB assay.
Acute Coronary Syndrome
No ST Elevation
NSTEMI
ST Elevation
Unstable Angina
Myocardial Infarction
NQMI QwMI
Fig. 1  Clinical classification of
acute coronary syndromes. NQMI
- non-Q wave myocardial infarc-
tion; NSTEMI - non-ST elevation
myocardial infarction Q wave; Q
wave MI - Q wave myocardial in-
farction; ST - ST segment of ECG
tracing.
Reproduced with permission of
Elsevier Science from Eur Heart
J, Vol 21 issue 18, Sept 2000.
The relative risk for TnT positive patients
was, in a meta-analysis reported by Heiden-
reich, 3.9 for mortality and 3.8 for death or
non-fatal recurrent MI. Ottani et al. in a recent
work (Am. Heart J. – 2000) conclude that the
adverse prognostic significance of a positive
troponin test has been demonstrated by multi-
ple clinical investigators, across multiple trials,
involving multiple patient groups from differ-
ent countries, indicating that the observation is
a robust one.
Patients with a positive TnT test are consi-
dered to benefit from aggressive pharmacologi-
cal therapy with IIb/IIIa glycoprotein inhibitors
and, according to some authors, should be se-
lected for early invasive strategy. However, the
FRISC study showed no correlation between
the severity of underlying CAD and the TnT
level but did show a progressive increase in
the odds of TIMI-3 flow with increasing TnT
levels. Based on these observations Antman
describes a U-shaped curve relating TnT mea-
surements and the rate of MI through one year.
Patients with only slightly elevated levels of
TnT or TnI do not benefit from IIb/IIIa GP
inhibitors with respect to prevention of death
or non-fatal MI by 30 days. Those with inter-
mediate values of the troponins have the maxi-
mum benefit, whereas those with higher bio-
marker levels show progressively less benefit
compared with the intermediate group. These
results, according to this author, came from de-
tailed observation of the results of both the
FRISC-II study and the PRISMA-Plus trial. 737
Accordingly patients with intermediate ele-
vation of troponin values have not yet lost
substantial amounts of myocardium and are
ideal candidates for more effective antithrom-
botic therapy and prompt referral for an early
invasive approach supported by i.v. glycopro-
tein IIb/IIIa inhibitors. Those patients with
higher levels of troponin have increasing
amounts of completed myocardial damage and
are less likely to benefit from i.v. GP IIb/IIIa
inhibitors. They may have severe 3-vessel dis-
ease and decreased LV function and should be
referred early for bypass surgery (Fig. 3).
PERCUTANEOUS CORONARY
INTERVENTION
An increase of cardiac markers after coro-
nary angioplasty or implantation of coronary
artery stents, or both, is indicative of cell 
death (Consensus Document-ESC/ACC –
2000). This elevation occurs in a setting of
myocardial ischemia and according to the new
criteria should be labelled as an MI.
About five years ago, the group of E. Topol
presented data on the prognostic significance
of transient, uncomplicated in-laboratory coro-
nary artery closure. In a population of about
five thousands percutaneous coronary interven-
tion (PCI) procedures, 88 had a transient, un-
complicated, in-laboratory vessel closure.
When the procedure was associated with CK-
MB elevation there was a significant correla-
0
2
4
6
8
10
12
14
16
18
20
TnT <0.01 0.01-0.17 0.18-0.63 >0.63 µg/L
%
Death
MI
Fig. 2  Death and myocardial in-
farction (MI) rate at 12 months,
respectively, in relation to tropo-
nin T (tnT) levels.
Reproduced with permission of
Elsevier Science from JACC
2001;38:979:86.
tion with cardiac death (risk ratio, 1.25
P<0.0001); an increase in CK-MB was also the
most important correlate for major ischemic
events on follow-up. The authors (Abdelmeguid
et al) conclude that the determination of CK-
MB in this subset of patients has important
prognostic implications.
A study by Kini et al. was designed to eva-
luate the incidence and predictors of CK-MB
elevation after successful coronary interven-
tion, in 1,675 consecutive patients. CK-MB
elevation was detected in 313 patients
(18.7 %). Procedural complications or ECG
changes occurred in only 49 % of the CK-MB
elevation cases. Predictors of CK-MB elevation
on multivariate analysis were diffuse coronary
disease (p=0.02), systemic atherosclerosis
(p=0.002), stent use (p=0.04) and absence of
beta-blockers therapy (p=0.001). Adverse in-
hospital cardiac events were more frequent in
patients with more than 5 times CK-MB eleva-
tion. During a mean follow-up of one year the
incidence of death was not statistically differ-
ent between the two groups (1.6 % versus
1.3 %). The relevance and complexity of the
real meaning of myonecrosis after revascular-
ization procedures has been the subject of a738
recent review article by Califf et al. and repre-
sents a consensus among a group of resear-
chers with data on this subject. Table I sum-
marizes the main mechanisms involved.
Table I
Elevated biomarkers after PCI
1. Minor branch occlusion
2. Thrombus in the vessel
3. Intimal dissection
4. Coronary spasm
5. Distal embolization
Heeschen et al. recently studied the cardio-
vascular risk and therapeutic benefit of coro-
nary interventions for patients with unstable
angina according to TnT status. Three hundred
and fifty-one patients with unstable angina
(UA) were included; TnT was elevated in
36 %. In a follow-up of 30 days the TnT pos-
itive patients were more refractory to medical
treatment (78 % vs. 44 %); had a higher in-
cidence of cardiac events (6.4 %n vs. 0.4 %);
and the angiograms documented more severe
CAD requiring revascularization (69 % vs.
50 %). The authors conclude that TnT identi-
fied high-risk patients with UA with a higher
event rate prior to and in association with PCI.
Likelihood of Events
With Intravenous
GP IIb/IIIa Inhibitor
Increased
No effect
Decreased
NOT Helpful
Helpful
Neg Positive
Troponin Level
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Fig. 3  Proposal for therapeutic decision making based on quantitative troponin results. The U-shaped relationship between absolute
levels of troponin and the risk of death and myocardial infarction following administration of intravenous glycoprotein (GP)IIb/IIIa inhi-
bitors is shown. Patients with undectectable troponin levels or just barely elevated troponin levels are at low risk and unlikely to bene-
fict from an intravenous GPIIb/IIIa. inhibitor. Those with intermediate levels of troponin derive the greatest benefict while those with
progressively higher levels of troponin have increasing amounts of completed myocardial damage and are less likely to benefict from
intravenous GPIIb/IIIa inhbitors. See text for further discussion. The relationship shown in this figure is in part based on data from
Lindahl et al. (10) and Heeschen et al. (11). Reproduced with permission of Elsevier Science. JACC 2001;38:987-90.
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In an editorial comment to this paper Bre-
ner and Topol raise the question why myocar-
dial necrosis of such a limited extent should
be associated with unfavourable outcome. They
establish a link between the diseased epicar-
dial artery and the events occurring in the mi-
crocirculation after plaque fissure or rupture.
The ruptured atherosclerotic plaque disturbs
epicardial flow and promotes the deposition
and activation of platelets, with distal embol-
ization and microvascular obstruction. The au-
thors present a new pathophysiologic paradigm
of plaque rupture, embolization and microcir-
culatory dysfunction which would explain the
unfavourable prognostic of this limited necro-
sis (Table II).
Table II
Troponin, embolization and microvascular
integrity
Ruptured atherosclerotic plaque

platelet deposition and activation

Distal embolization of the plaque-platelet aggregate

Microvascular obstruction

Myocardial necrosis

TnT elevation
Brener and Topol. Eur Heart J 2000;21:1117.
What are the clinical implications of the
new definition of MI? In the recent meeting of
the ACC, Meier et al. presented data from the
University of Michigan, collected for a period
of 8 months. Three hundred and five patients
with enzyme elevations were separated into 2
groups: Group A with positive CK-MB (n=264)
regardless of troponin status and group B with
negative CK-MB but positive TnI (n=41). Pa-
tients in group B had a shorter hospital stay
and fewer events (without statistical signifi-
cance). The decision to include troponins in the
diagnostic criteria of MI resulted in a 16 % in-
crease in the annual number of MI diagnosed.
The GRACE investigators examined the MI
rates and prognostic value of peak CK-MB and
troponins (I/T) in 3,420 patients. The authors
concluded that the addition of troponin leads
to as many as 25 % additional ACS patients
meeting the criteria for the diagnosis of MI.
This group of patients experiences a 3-fold in-
crease in short-term mortality when compared
to normal enzyme levels and a 1.5-fold in-
crease compared to the traditional cardiac
enzyme definition.
So, in conclusion, we may say that the new
definition of AMI allows us for the first time to
distinguish between unstable angina and myo-
cardial infarction.
This is important on clinical grounds be-
cause any amount of myocardial damage im-
plies worse prognosis for the patients and so
allows appropriate secondary prevention.
The epidemiological implications are im-
portant and should be emphasized. The appli-
cation of the new diagnostic criteria for MI will
cause the recorded incidence of MI to rise and
the case fatality rate to fall.
Modification of the definition of MI is going
to have an impact on the selection of patients
for clinical trials, but may enable us to sepa-
rate, with more rigorous criteria, between un-
stable angina and myocardial infarction. The
homogeneity of the population may help to
analyze the results and clarify the conclusions.
REMARK 1
Biochemical testing is the only method by
which non-Q wave AMI can be diagnosed and
by which the majority of patients presenting
with suspected ACS can have AMI excluded.
P.O. Collinson Eur Heart J 1998; Suppl N-16.
REMARK 2
About one third of patients with ST-elevation
who would previously have been diagnosed as
experiencing UA on the basis of normal CK-
MB levels are now diagnosed as having
NSTEMI because of dectectable troponin le-
vels. Braunwald et al. JACC 2000;36:970.
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